



GP/1614#C

RECEIVED
FEB 01 2002
TECH CENTER 1600/2900
FEB 26 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dambinova, Svetlana A.

Serial No.: 09/922,011

Filed: August 2, 2001

For: Rapid Panel of Biomarkers in Laboratory Blood
Tests for TIA/Stroke

)
)
)
) Art Unit: 1614
)
)
)
)

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Clark G. Sullivan

Clark G. Sullivan
Reg. No. 36,942

King & Spalding
45th Floor, 191 Peachtree Street, N.E.
Atlanta, GA 30303
404.572.4600
K&S Docket: 08805.105001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on January 17, 2002.

Clark G. Sullivan


Clark G. Sullivan, Reg. No. 36,942

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 09/922,011 |
| Filing Date | August 2, 2001 |
| First Named Inventor | Dambinova, Svetlana A. |
| Group Art Unit | 1614 |
| Examiner Name | |
| Attorney Docket Number | 08805.105001 |

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------------|--------------------------|----------------------|--------------------------------------|--|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|------------------------|--------------------------|-------------------------|--------|--------------------------------------|---|--|--|----------------|
| | | Office ³ | Number | Kind Code ² (if known) | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|--|----------------|
| | CA | Dambinova, et al., "Autoantibodies to Subtypes of Glutamate Receptors as a Hallmarks of Brain Damage: Diagnostic Significance for Paroxysmal Activity and Ischemia." <i>Journal of Higher Nervous Activity</i> . 1997. Vol. 47 (2), pp. 151-156. | |
| | CB | Gusev, et al., "Neuroprotective Effects of Glycine for Therapy of Acute Ischaemic Stroke." <i>Cerebrovasc Dis</i> 2000; 10:49-60. | |
| | CC | Gahring, et al., Autoantibodies to Neuronal Glutamate Receptors in Patients with Paraneoplastic Neurodegenerative Syndrome Enhance Receptor Activation." <i>Molecular Medicine</i> , Volume 1, Number 3, March 1995, 245-253. | |
| | CD | Rogers, S.W., "Autoantibodies to Glutamate Receptor GluR3 in Rasmussen's Encephalitis." <i>Ovid: Science</i> , Volume 265(5172), 29 July 1994, pp. 648-651. | |
| | CE | Dambinova, et al., "Monitoring of Brain Spiking Activity and Autoantibodies to N-Terminus Domain of GluR1 Subunit of AMPA Receptors in Blood Serum of Rats with Cobalt-Induced Epilepsy." <i>Journal of Neurochemistry</i> , Lippincott-Raven Publishers, Philadelphia. | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
 FEB 01 2002
 TECH CENTER 1600/2900
 FEB 26 2002

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. PTO/SF 08A (08-00)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 09/922,011 |
| Filing Date | August 2, 2001 |
| First Named Inventor | Dambinova, Svetlana A. |
| Group Art Unit | 1619 |
| Examiner Name | |
| Attorney Docket Number | 08805.105001 |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | |
|---------------------|-----------------------|---|---|
| | CF | Dambinova, et al., "The presence of autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptor in the blood serum of patients with epilepsy." <i>Journal of Neurological Sciences</i> , 152 (1997), 93-97. ✓ | |
| | CG | Vincent, et al., "Pathogenic autoantibodies to neuronal proteins in neurological disorders." <i>Journal of Neuroimmunology</i> , 100 (1999) 169-180. ✓ | |
| | CH | Lipton, et al., Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor." <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 5923-5928, May 1997. ✓ | |
| | CI | Meldrum, B.S., "Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology ¹ ." <i>Journal of Nutrition</i> . 2000; 130:1007S-1015S. ✓ | |
| | CJ | Dávalos, et al., "Neurological Deterioration in Acute Ischemic Stroke: Potential Predictors and Associated Factors in the European Cooperative Acute Stroke Study (ECASS) 1." <i>Ovid: Davalos: Stroke</i> , Volume 30(12), December 1999, 2631-2636. ✓ | |
| | CK | Davalos, et al., "Duration of Glutamate Release After Acute Ischemic Stroke." <i>Ovid: Davalos: Stroke</i> , Volume 28(4), April 1997, 708-710. ✓ | |
| | CL | Castillo, et al., "Neuroexcitatory Amino Acids and Their Relation to Infarct Size and Neurological Deficit in Ischemic Stroke." <i>Ovid: Castillo: Stroke</i> , Volume 27(6), June 1996, 1060-1065. ✓ | |
| | CM | Yamamoto, et al., "CSF and ECF Glutamate Concentrations in Head Injured Patients." <i>Acta Neurochir</i> (1999) [Suppl] 75:17-19. ✓ | |
| | CN | Castillo, et al., "Progression of ischaemic stroke and excitotoxic aminoacids." <i>Lancet</i> 1997; 349: 79-83. ✓ | |
| | CO | Gusev, et al., "The level of autoantibodies to glutamate receptors in the blood serum of patients in the acute period of ischemic stroke." <i>Ovid Technologies, Inc.</i> , 2000-2001, Version rel4.5.0, SourceID 1.5686.1.73. (Abstract) ✓ | ✓ |
| | CP | Vila, et al., "Plasma homocysteine levels in patients with ischemic cerebral infarction." <i>Med Clin (Barc)</i> 1998 May 9; 110(16): 605-8. (Abstract) ✓ | ✓ |
| | CQ | Hill, et al., "Biochemical markers in acute ischemic stroke." <i>Canadian Medical Association Journal</i> , April 18, 2000; 162:1139-40. ✓ | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
FEB 01 2002
TECH CENTER 1600129001

RECEIVED
FEB 26 2002
TECH CENTER 1600129001